Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 9/20 | 0.45 |
| ▸ | BRAF | P15056 | 4/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL30638609 | 0.99 | AR (0.47) | ARGRM4KDRBRAFCDK8 | |
| SCHEMBL24516620 | 0.92 | AR (0.46) | ARGRM4KDRBRAFCDK8 | |
| SCHEMBL24515710 | 0.92 | AR (0.46) | ARGRM4KDRBRAF | |
| SCHEMBL24516621 | 0.92 | AR (0.46) | ARGRM4KDRBRAFCDK8 | |
| Hydrochloric Acid SCHEMBL26613248 | 0.91 | AR (0.45) | ARGRM4KDRBRAFCDK8 | |
| SCHEMBL24515714 | 0.84 | AR (0.51) | ARGRM4KDRBRAFCDK8 | |
| SCHEMBL24515205 | 0.84 | AR (0.45) | ARGRM4KDRBRAFCDK8 | |
| SCHEMBL24515203 | 0.84 | AR (0.45) | ARGRM4KDRBRAFCDK8 | |
| SCHEMBL24515852 | 0.83 | AR (0.44) | ARGRM4KDRBRAFCDK8 | |
| SCHEMBL24515838 | 0.83 | AR (0.44) | ARGRM4KDRBRAFCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | AR 1660/4885GRM4 2583/4885KDR 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.